The Costs of Industry-Sponsored Drug Trials in Canada
View abstract on PubMed
Summary
This summary is machine-generated.The total cost of industry-sponsored drug clinical trials (CTs) in Canada in 2016 was approximately $2.1 billion. Drug costs represented the largest portion of this expenditure, with significant costs in Ontario and Quebec.
Area Of Science
- Health Economics
- Pharmaceutical Research
- Clinical Trial Management
Background
- Industry-sponsored drug clinical trials (CTs) are crucial for pharmaceutical innovation.
- Accurate cost estimation of these trials is essential for resource allocation and policy-making.
- Understanding the economic impact of CTs in Canada is vital for the healthcare sector.
Purpose Of The Study
- To estimate the provincial and nationwide economic costs associated with industry-sponsored drug clinical trials (CTs) conducted in Canada.
- To analyze the cost breakdown, including drug expenses and patient services.
- To identify regional cost variations within Canada.
Main Methods
- Utilized the Aggregate Analysis of ClinicalTrials.gov (AACT) database for industry-sponsored drug CTs completed in Canada in 2016.
- Estimated study drug costs using prevailing market prices.
- Determined management and patient service costs based on industry contract data.
Main Results
- A total of 394 CTs were analyzed, involving 20,126 Canadian enrollees across 2,039 facilities.
- Average drug costs per patient were $89,680, with higher costs observed in cancer CTs ($216,876) versus non-cancer CTs ($65,274).
- The total estimated cost for industry-sponsored drug CTs in 2016 was $2.1 billion, with drug costs comprising $1.8 billion. Ontario and Quebec incurred the highest provincial costs.
Conclusions
- Industry-sponsored drug CTs completed in Canada in 2016 represented a significant economic investment, valued at approximately $2.1 billion at market prices.
- Drug acquisition costs formed the predominant component of the overall trial expenditure.
- Provincial cost distribution highlights Ontario and Quebec as major centers for these trials.
Related Concept Videos
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...